1. Sun Pharmaceutical Industries
stock logo

94% Buy

Sun Pharmaceutical Industries Share Price

SUNPHARMA

₹1,494.50+₹27.25 (1.86%) TodayLast updated on 24 Jun, 2024 | 03:55 PM IST
₹1,475.05₹1,502.90
L
Show Current Price
H
  • News

  • Company overview

  • Fundamentals

  • Events

  • F&O (Option chain)

  • More

Company overview

Financial performance

arrow

Market cap

Market Cap Switch₹3,63,739 Crs

Open

₹1,475.05

Close

₹1,467.25

Circuit range

₹1,613.95 - ₹1,320.55

Day range

₹1,475.05 - ₹1,502.90

Year range

₹977.30 - ₹1,638.85

Volume

37,26,155

Avg. traded

₹1,493.30

Revenue (12m)

₹48,497 Crs

Sun Pharmaceutical Industries

Sun Pharmaceutical Industries Ltd is the world’s fourth-largest specialty generic pharmaceutical company. With a network of over 40 manufacturing facilities, the company distributes medicines to more than over 100 countries worldwide. The company has a global employee base of over 41,000.

The company’s recent acquisition of Concert Pharmaceuticals Inc in the United States has granted it access to the late-stage asset deuruxolitinib, which has completed Phase-3 studies for treating alopecia areata. Founded in 1983, Sun Pharma has a market capitalisation of ₹2,98,705 crore as of December 19, 2023. Sun Pharma share price has gained 114% in the last 3 years.

Business portfolio

The company manufactures and markets a wide range of pharmaceutical formulations, which include generics, branded generics, over-the-counter, antiretrovirals, intermediates and active pharmaceutical ingredients. In specialty medications, Sun Pharma has a portfolio of patent-protected drugs. With focus on dermatology, ophthalmology and oncology, the company aims to improve patient outcomes by addressing unmet medical needs and enhancing convenience through diverse dosage forms.

Sun Pharma provides high-quality generic and branded medicines to patients and healthcare professionals in over 100 countries. These medicines are available in tablets, capsules, injectables, inhalers, ointments, creams and liquids.

The therapeutic segments covered by the company’s portfolio includes psychiatry, anti-infectives, neurology, cardiology, orthopaedics, diabetology, gastroenterology, ophthalmology, nephrology, urology, dermatology, gynaecology, respiratory, oncology, dental and nutritionals. Sun Pharma consistently ranks among the leading companies in these therapy areas. Presently, it’s one of the top companies in the United States, having introduced a number of speciality items.

When it comes to over-the-counter medications, Sun Pharma’s range is diverse. Its flagship OTC brands such as Faringosept (sore throat), Revital (vitamins) and Volini (topical analgesics) are available globally.

With regards to active pharmaceutical ingredients (APIs), Sun Pharma began producing them in 1995. The company manufactures more than 300 APIs that are sold in over 60 countries. These are manufactured in 14 sites spread across India, Hungary, the United States, Israel and Australia.

Sun Pharma provides a selection of antiretroviral (ARV) drugs that have been prequalified by the WHO. The company works with groups like the Clinton Health Access Initiative (CHAI) to lower the cost of triple medication combinations and provides ARVs to various National AIDS treatment programmes in Africa.

Bioequivalent ARV medications and APIs are produced at WHO-prequalified facilities in India, a PIC/S-approved facility in South Africa and a plant in Russia, all of which are part of Sun Pharma’s portfolio.

Financial highlights

In FY23, the total income of the company stood at ₹44,520 crore, compared to ₹39,576 crore in the previous fiscal year. The company’s net profit after minority interest for FY23 was ₹8,473.6 crore, compared to ₹3,272.7 crore in FY22. Its earnings per share (EPS) for FY23 stood at ₹35.3, compared to ₹13.6 in FY22. The company made a capital expenditure of ₹60 crore in FY23 as against ₹87 crore in FY22. The research and development (R&D) expenditure stood at ₹2,367.6 crore in FY23.

Sun Pharmaceutical Industries Key indicators

arrow

52 week high

₹1,638.85

52 week low

₹977.30

P/E ratio

37.99

P/B ratio

5.71

ROE

7%

ROCE

7.28%

Dividend yield

0.92%

Debt/Equity ratio

0.32

EPS

7.05

Learn more

Investment checklist: (5/6)

arrow
check status

Equity returns

check status

Dividend returns

check status

Safety factor

check status

Growth factor

check status

Debt vs Equity

check status

Profit factor

The investment checklist helps you understand a company's financial health at a glance and identify quality investment opportunities easily

Analyst ratings:

Buy

arrow

Buy

94%

Hold

3%

Sell

3%

This analysis is based on the reviews of 33 experts in the last 7 days

Brands by Sun Pharmaceutical Industries

arrow
brand logo

SPARC

Fundamentals

Financial ratios

arrow
  • Profitability

  • Operational

  • Valuation

Operating profit margin

31.01%

Net profit margin

7.77%

ROE

7%

ROA

4.1%

ROCE

7.28%

Learn more

Sun Pharmaceutical Industries Shareholder returns

arrow

1 day

-0.25%

1 week

-2.88%

1 month

-4.78%

3 months

-6.26%

1 year

+47.92%

3 years

+118.55%

5 years

+283.29%

Sun Pharmaceutical Industries Share Price history

arrow
DayOpenCloseDay’s change
Fri, Jun 21 2024
₹1,480.10
₹1,467.25
-0.25%
Thu, Jun 20 2024
₹1,487.95
₹1,471.00
-2.19%
Wed, Jun 19 2024
₹1,524.95
₹1,504.00
-1.11%
Tue, Jun 18 2024
₹1,522.60
₹1,520.95
+0.33%
Fri, Jun 14 2024
₹1,513.85
₹1,516.00
+0.34%
Thu, Jun 13 2024
₹1,514.60
₹1,510.80
+0.26%
Wed, Jun 12 2024
₹1,500.00
₹1,506.85
+0.47%
Tue, Jun 11 2024
₹1,524.00
₹1,499.75
-0.88%

Shareholding info

arrow

Promoters (54.48%)

Mutual Funds (12.21%)

Retail and other (8.97%)

Foreign institutions-FII (17.72%)

Other domestic institutions (6.61%)

Promoters

Learn more

Events

Corporate actions

arrow
  • Dividend • ₹5/share

    Ex date 12 Jul 2024

    expand tab
  • Dividend • ₹8.5/share

    Ex date 09 Feb 2024

    expand tab
  • Dividend • ₹4/share

    Ex date 28 Jul 2023

    expand tab
  • Dividend • ₹7.5/share

    Ex date 08 Feb 2023

    expand tab
  • Dividend • ₹3/share

    Ex date 19 Aug 2022

    expand tab
  • Dividend • ₹7/share

    Ex date 09 Feb 2022

    expand tab

Learn more

Frequently asked questions